A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea

Luyao Zhang; Xiaoling Chen; Yue Wu; Mei Zhou; Chengbang Ma; Xinping Xi; Tianbao Chen; Brian Walker; Christopher Shaw; Lei Wang

doi:10.1038/s41598-018-24206-4

A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea

Luyao Zhang, Xiaoling Chen, Yue Wu, Mei Zhou, Chengbang Ma, Xinping Xi, Tianbao Chen, Brian Walker, Christopher Shaw, Lei Wang

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

215 Downloads (Pure)

Abstract

The first amphibian skin secretion-derived Bowman-Birk type chymotrypsin inhibitor is described here from the Asian green frog, Hylarana erythraea, and was identified by use of molecular cloning and tandem mass spectrometric amino acid sequencing. It was named Hylarana erythraea chymotrypsin inhibitor (HECI) and in addition to inhibition of chymotrypsin (Ki = 3.92 ± 0.35 μM), the peptide also inhibited the 20 S proteasome (Ki = 8.55 ± 1.84 μM). Additionally, an analogue of HECI, named K9-HECI, in which Phe9 was substituted by Lys9 at the P1 position, was functional as a trypsin inhibitor. Both peptides exhibited anti-proliferation activity against the human cancer cell lines, H157, PC-3 and MCF-7, up to a concentration of 1 mM and possessed a low degree of cytotoxicity on normal cells, HMEC-1. However, HECI exhibited higher anti-proliferative potency against H157. The results indicate that HECI, inhibiting chymotryptic-like activity of proteasome, could provide new insights in treatment of lung cancer.

Original language	English
Article number	5851
Number of pages	9
Journal	Scientific Reports
Volume	8
DOIs	https://doi.org/10.1038/s41598-018-24206-4
Publication status	Published - 11 Apr 2018

Access to Document

10.1038/s41598-018-24206-4Licence: CC BY

A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea
Copyright 2018 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 1.68 MBLicence: CC BY

Fingerprint Dive into the research topics of 'A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea'. Together they form a unique fingerprint.

Lei Wang
- l.wang@qub.ac.uk
- School of Pharmacy - Lecturer
Person: Academic

Cite this

@article{db6279c3b8a3453ea5ba1908f0f9eca5,

title = "A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea",

abstract = "The first amphibian skin secretion-derived Bowman-Birk type chymotrypsin inhibitor is described here from the Asian green frog, Hylarana erythraea, and was identified by use of molecular cloning and tandem mass spectrometric amino acid sequencing. It was named Hylarana erythraea chymotrypsin inhibitor (HECI) and in addition to inhibition of chymotrypsin (Ki = 3.92 ± 0.35 μM), the peptide also inhibited the 20 S proteasome (Ki = 8.55 ± 1.84 μM). Additionally, an analogue of HECI, named K9-HECI, in which Phe9 was substituted by Lys9 at the P1 position, was functional as a trypsin inhibitor. Both peptides exhibited anti-proliferation activity against the human cancer cell lines, H157, PC-3 and MCF-7, up to a concentration of 1 mM and possessed a low degree of cytotoxicity on normal cells, HMEC-1. However, HECI exhibited higher anti-proliferative potency against H157. The results indicate that HECI, inhibiting chymotryptic-like activity of proteasome, could provide new insights in treatment of lung cancer.",

author = "Luyao Zhang and Xiaoling Chen and Yue Wu and Mei Zhou and Chengbang Ma and Xinping Xi and Tianbao Chen and Brian Walker and Christopher Shaw and Lei Wang",

year = "2018",

month = apr,

day = "11",

doi = "10.1038/s41598-018-24206-4",

language = "English",

volume = "8",

journal = "Nature Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea

AU - Zhang, Luyao

AU - Chen, Xiaoling

AU - Wu, Yue

AU - Zhou, Mei

AU - Ma, Chengbang

AU - Xi, Xinping

AU - Chen, Tianbao

AU - Walker, Brian

AU - Shaw, Christopher

AU - Wang, Lei

PY - 2018/4/11

Y1 - 2018/4/11

N2 - The first amphibian skin secretion-derived Bowman-Birk type chymotrypsin inhibitor is described here from the Asian green frog, Hylarana erythraea, and was identified by use of molecular cloning and tandem mass spectrometric amino acid sequencing. It was named Hylarana erythraea chymotrypsin inhibitor (HECI) and in addition to inhibition of chymotrypsin (Ki = 3.92 ± 0.35 μM), the peptide also inhibited the 20 S proteasome (Ki = 8.55 ± 1.84 μM). Additionally, an analogue of HECI, named K9-HECI, in which Phe9 was substituted by Lys9 at the P1 position, was functional as a trypsin inhibitor. Both peptides exhibited anti-proliferation activity against the human cancer cell lines, H157, PC-3 and MCF-7, up to a concentration of 1 mM and possessed a low degree of cytotoxicity on normal cells, HMEC-1. However, HECI exhibited higher anti-proliferative potency against H157. The results indicate that HECI, inhibiting chymotryptic-like activity of proteasome, could provide new insights in treatment of lung cancer.

AB - The first amphibian skin secretion-derived Bowman-Birk type chymotrypsin inhibitor is described here from the Asian green frog, Hylarana erythraea, and was identified by use of molecular cloning and tandem mass spectrometric amino acid sequencing. It was named Hylarana erythraea chymotrypsin inhibitor (HECI) and in addition to inhibition of chymotrypsin (Ki = 3.92 ± 0.35 μM), the peptide also inhibited the 20 S proteasome (Ki = 8.55 ± 1.84 μM). Additionally, an analogue of HECI, named K9-HECI, in which Phe9 was substituted by Lys9 at the P1 position, was functional as a trypsin inhibitor. Both peptides exhibited anti-proliferation activity against the human cancer cell lines, H157, PC-3 and MCF-7, up to a concentration of 1 mM and possessed a low degree of cytotoxicity on normal cells, HMEC-1. However, HECI exhibited higher anti-proliferative potency against H157. The results indicate that HECI, inhibiting chymotryptic-like activity of proteasome, could provide new insights in treatment of lung cancer.

U2 - 10.1038/s41598-018-24206-4

DO - 10.1038/s41598-018-24206-4

M3 - Article

VL - 8

JO - Nature Scientific Reports

JF - Nature Scientific Reports

SN - 2045-2322

M1 - 5851

ER -